HRA Pharma (United Kingdom)

Recent papers from HRA Pharma (United Kingdom)

1. Beyond congenital anomalies, the impact of sodium valproate exposure in utero on long‐term health and well‐being: A contribution from the ConcePTION projectEpilepsia · 2026
2. A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.Journal of Clinical Oncology · 2026
3. Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLCCancer Research · 2026
4. Efficacy and safety of a nutritional supplement based on vitamins, minerals, amino acids and plant extracts on a large population of older adults experiencing fatigueNutrición Hospitalaria · 2026
5. Neurodevelopmental outcomes in children and adults with Fetal Valproate Spectrum Disorder: A contribution from the ConcePTION projectNeurotoxicology and Teratology · 2023
6. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular ruptureHuman Reproduction · 2010
7. Innate immune responses to mycobacteria and the downregulation of atopic responsesCurrent Opinion in Allergy and Clinical Immunology · 2003